Tae-Hyun Yoo, Soon Jun Hong, Sunggyun Kim, Seokjoon Shin, Dong Ki Kim, Jung Pyo Lee, Sang Youb Han, Sangho Lee, Jong Chul Won, Young Sun Kang, Jongha Park, Byoung-Geun Han, Ki-Ryang Na, Kyu Yeon Hur, Yong-Jin Kim, Sungha Park
As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD. This was a randomized, multicenter, double-blind, 4-parallel-group, dose-titration, phase III study designed to compare the efficacy of fimasartan and losartan in reducing albuminuria in patients with DKD (NCT02620306). The primary endpoint was the rate of change in albuminuria from baseline to week 24...
September 20, 2022: Hypertension Research: Official Journal of the Japanese Society of Hypertension